Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology

Jubilant Therapeutics is preparing to begin Phase II and first-in-human trials later in 2023 with two Orphan Drug Designations, an advantageous safety profile, and enhanced therapeutic indices. The company's pipeline uses their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine to identify candidate molecules with improved therapeutic indices and the ability to penetrate ..